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Chronic bronchitis; Influenza; Vaccine; Coverage Summary Influenza vaccination is recommended for people with chronic bronchitis (CB) because they have a higher risk of influenza-related complications, hospitalizations, and death during seasonal influenza epidemics.
This study sought to evaluate influenza vaccination coverage among adults with CB and analyze the factors (predictors) linked to compliance with vaccination recommendations.
Individual data from adults aged 40 years included in the Spanish Health Survey conducted in 2006 were used. Subjects were classified as chronic bronchitis sufferers if they answered affirmatively to the question: ''has your doctor told you that you are currently suffering from chronic bronchitis?''. To assess influenza vaccination status we used the question, ''did you have a flu shot in the latest campaign?''. Independent variables analyzed included sociodemographic, health-related variables, self-reported presence of other concomitant chronic diseases, and use of health-care services.
The percentage of subjects who were reported to be suffering from CB was 6.6% (N Z 1320, 95% CI 6.2e6.9%). The influenza vaccination coverage among CB sufferers was 63.6% compared with 48.6% for nonsufferers (p < 0.05). The predictors significantly associated with a higher likelihood of receiving the vaccine among adult CB sufferers were: higher age; male gender; nonsmoker or ex-smoker status; doing physical exercise; and suffering from concomitant asthma or diabetes.
We conclude that influenza vaccination coverages among Spanish adults suffering from CB are below desirable levels; thereby making it necessary for strategies to be implemented aimed at improving the use of influenza vaccine among such patients. ª 2009 Elsevier Ltd. All rights reserved.
Introduction
Subjects suffering from chronic lung diseases, including chronic bronchitis (CB), have a higher risk of influenzarelated complications, hospitalizations, and death during seasonal influenza epidemics. 1e6 In Spain, a study conducted to estimate excess hospital admissions of influenza-related diseases during four epidemic influenza periods observed that chronic bronchitis was the second leading influenza-related disease after pneumonia. 4 Schanzer et al estimated age-specific influenza-attributable mortality rates in Canada, stratified by the presence of chronic conditions, from 1994 to 2000, and reported that there were approximately 4000 influenza-attributable deaths per year (equivalent to a rate of 14 per 100,000 population), with chronic lung disease being present in over 50% of all patients whose death was attributed to influenza. 5 The effectiveness of influenza vaccination among patients with chronic respiratory diseases has been shown in both clinical trials and observational studies. In a systematic review of the Cochrane database, in which six randomized clinical trials with influenza vaccines in chronic obstructive pulmonary disease (COPD) sufferers were assessed, a significant decrease in the total number of exacerbations was observed among vaccinated subjects versus those who received placebo. 6 In these trials, influenza vaccination also reduced the development of severe respiratory complications and hospitalization by 50e80%, and death from both respiratory disease and all causes by 40e55%. 6 Seasonal influenza vaccine for patients with chronic pulmonary diseases is recommended by the public health authorities in USA and all European countries. 9, 10 Since 1992, the Spanish Ministry for Health and Consumer Affairs has included all subjects who suffer from chronic lung diseases in its annual influenza vaccine recommendations, with vaccination being administered free of charge in all such cases.
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Developing and implementing methods for the measurement of and feedback about the progress of national and local influenza control programs, including vaccine coverage, form part of the priority goals set by the World Health Organization and European Union Public Health Program. 9, 12, 13 Coverage studies enable compliance with prevailing guidelines to be ascertained, associated factors to be studied, and non-complying subjects to be characterized and identified. 9,12e16 Furthermore, these studies are of help for the purposes of drawing up appropriate strategies to improve goals, providing data in support of decision-making, and managing vaccination programs. 9,12e16 To our knowledge, no specific studies on influenza vaccination coverage and factors associated with vaccine uptake, using a representative sample of adults suffering from chronic bronchitis, have been conducted in Spain. Previous studies that included subjects suffering from ''chronic lung diseases'' have been published, and report vaccination coverages ranging from 41% to figures in excess of 87%. Based on data drawn from the 2006 National Health Survey, this study aimed at:
ascertaining influenza vaccination coverages among
Spanish adults suffering from chronic bronchitis; 2. analyzing which sociodemographic, health-related variables, and use of health-care services variables were associated with the likelihood of Spanish chronic bronchitis sufferers being vaccinated.
Patients and methods
A descriptive cross-sectional study was conducted on influenza vaccination coverage nationwide, using data drawn from the 2006 Spanish National Health Survey (NHS For study purposes, subjects aged 40 years and over were selected. We identified individuals suffering from chronic bronchitis as those that answered ''yes'' to the question, ''has your doctor told you that you are currently suffering from chronic bronchitis?''.
To assess influenza vaccination status we considered the response (yes or no) to the question, ''did you have a flu shot in the latest campaign?''. The following were analyzed as independent variables: (a) sociodemographic characteristics, such as age, sex, educational level (age of conclusion of formal education), and monetary income; (b) health-related variables, namely, (1) self-rated health status, (2) smoking habit (nonsmokers, ex-smokers, and current smokers), (3) obesity (body mass index 30, BMI was calculated from self-declared weight and height), (4) alcohol consumption, (5) physical exercise, and (6) selfreported presence of other concomitant chronic diseases (asthma, chronic heart disease, diabetes and depression); and (c) use of health-care services, i.e., (1) physician visits in the preceding four weeks, (2) hospitalizations in the preceding 12 months, and (3) emergency room attendance in the preceding 12 months. Among vaccinated subjects, we then analyzed the reasons for which vaccine had been received. These included three possible categories, namely, ''on doctor's orders'', ''on request'', and ''vaccination in the workplace''.
Statistical analysis
We first estimated the prevalence of Spanish adults who suffered from chronic bronchitis (CB), described their distribution according to the study variables, and compared these figures against those for the non-CB population. Second, we estimated and compared age-and sex-adjusted vaccination coverages, among those with and without CB, according to the study variables.
In addition, we also described the reasons given by CB sufferers for having been vaccinated.
The c 2 statistical method was used for bivariate comparison of proportions, and statistical significance was set at two-tailed a < 0.05.
Third, multivariate logistic regression models were generated so that, by using influenza vaccination as the dependent variable, we could then determine which of the variables covered was independently associated with influenza vaccination (predictors) among CB sufferers.
The logistic regression multivariate model was built using the ''enter modelling'' method. The process included four steps: first, bivariate analysis of each variable; second, selection of variables for the multivariate analysis. We included all the variables whose bivariate tests were significant and those we considered scientifically relevant according to the references reviewed. Third, in order to fit the multivariate model the importance of each variable included in the model was verified. To do this we examined the Wald statistic for each variable and compared each estimated coefficient with the coefficient from the bivariate model containing only that variable. Variables that did not contribute to the model based on this criterion were eliminated and a new model was fitted. The new model was compared to the old model using the LR test. This process of deleting, refitting and verifying continues until all the important variables were included in the model. Fourth, once the model was obtained, we looked more closely at the variables included (linearity) and checked for possible interactions.
Estimates were made using the ''svy'' (survey commands) functions of the STATA program, which enabled us to incorporate the sampling design and weights into all our statistical calculations (descriptive, Chi-squared, logistic regression).
Results
We analyzed a total of 20,060 records pertaining to individual adult (40 years) participants in the 2006 NHS. The percentage of subjects that reported that their doctor had told them they were suffering from CB was 6.6 (N Z 1320, 95% CI 6.2e6.9). Tables 1 and 2 show the distribution according to the study variables among CB sufferers and nonsufferers.
Spanish adults who suffered from CB were significantly older, more male predominant, and had a lower educational level and income than nonsufferers. Only 21.1% of CB sufferers regarded their health as having been good or excellent in the preceding year compared with 55.5% of nonsufferers. The prevalence of ex-smokers and obesity was significantly higher among adults with CB, while the prevalence of alcohol consumption and physical exercise was lower. All the chronic diseases analyzed and all the variables related with the use of health-care services showed significantly higher proportions among CB sufferers. Tables 3 and 4 show age-and sex-adjusted influenza vaccination coverages, broken down by the different variables analyzed.
The proportion of CB sufferers that reported having been vaccinated in the most recent campaign (coverage) was 63.6% compared with 48.6% for nonsufferers (p < 0.05).
Bivariate analysis of coverages among CB sufferers showed that the percentage of vaccinated subjects rose significantly with age, with the highest coverages being attained in subjects aged 75 years and over (79.8%). In contrast, vaccination uptake was significantly lower among females and among subjects with higher educational level or monthly income.
There was a significantly higher percentage of vaccination among adults with CB who were nonsmokers or exsmokers than among those who were smokers at the date of study. a Statistically significant association on comparing the distribution of variables between adults with and without chronic bronchitis.
Vaccination coverage was also higher among individuals who perceived their health more negatively and among those who reported doing physical exercise. A higher proportion of adults with CB who suffered from a concomitant chronic condition, such as asthma or diabetes, was vaccinated than were those without these concomitant diseases.
Lastly, adults with CB who had visited their physician in the preceding four weeks also showed higher coverages.
On being questioned as to their reason for having influenza vaccination, most vaccinated CB sufferers (86.9%) cited ''on doctor's orders'', while 9% checked the ''on request'' option. Among those without CB, these percentages were 76.8% and 17.1%, respectively (p < 0.05).
The results of the multivariate analysis are shown in Table 5 . The factors that were independently and significantly associated with a higher likelihood of receiving the vaccine (predictors) among adult CB sufferers were as follows: higher age; male gender; nonsmoker or ex-smoker status; doing physical exercise; and suffering from concomitant asthma or diabetes.
Discussion
The results of this study show that influenza vaccination coverage among Spanish adults suffering from chronic bronchitis is below desirable levels; and that 37.4% of them were not vaccinated in the last campaign and are thus possibly unprotected against influenza.
Using different methodologies, a number of authors have examined the prevalence and predictors of influenza vaccination among patients with chronic lung diseases.
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Table A study based on the 2005 Canadian Community Health Survey showed that coverage for subjects aged 12 or over suffering from ''emphysema or chronic bronchitis'' was 57%. 22 Studies using primary care databases and conducted in the United Kingdom for the period 2004/2005 obtained coverages of 36.1% and 23.8% for respiratory-disease sufferers aged 65 and <65 years, respectively. 23, 24 In 2004, Kroneman et al used telephone surveys to undertake a study in four European countries and reported that coverages among individuals aged 15 years with ''lung disease'' were 8% in Poland, 11% in Sweden, 20% in Germany, and 30% in Spain. 25 A study that targeted COPD sufferers over the age of 40 years attended to at Spanish health centers, observed a coverage of 87%. 17 Another study, which also used primary care computer databases, reported a coverage of 64.4% among elderly Spanish with chronic lung disease. 26 Until 2006, Spanish National Health Surveys (NHS) collected information on the presence of ''asthma and/or chronic bronchitis and/or emphysema'' in a single question, and consequently disease-specific coverage could not be estimated. 18, 19 The results yielded by our study and a comparison with other countries suggest that, as is the case with influenza vaccination coverage in subjects aged 65 and over, Spain possibly ranks among the developed countries having the highest coverages for this high risk group. 9 ,17e19,22e27 Few published studies have specifically analyzed the factors associated with a higher likelihood of influenza vaccination among subjects with chronic lung disease.
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The progressive increase in influenza coverage with age observed in our population has been reported in patients with chronic lung diseases or other high risk conditions by other studies conducted in Spain and elsewhere. 15,17e19,27e31 In Canada among the subjects suffering from COPD those aged >70 had 2.4 times more probability of being vaccinated than those aged >40.
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In Germany, Schoefer et al analyzed the vaccination status and its determinants in 2131 patients with asthma and/or COPD attended to at a specialized respiratorymedicine center, and found that vaccination rates displayed a significant upward trend with age (adjusted OR for age group with nine categories, 1.68; 95% CI 1.54e1.84). 27 In our population, as in that of other studies, 65 years marks the age from which a significantly higher proportion of subjects receive the influenza vaccine. Rather than being due to patient status, disease severity or the presence of concomitant chronic conditions, we feel that this is chiefly due to entry into the age group for which vaccination is universally indicated.
17e19,22e25, 27, 30, 31 This conclusion is coherent with the evidence that age-based strategies are more successful in increasing vaccine coverage than patient-selection strategies based on medical conditions. 32 When vaccination-related factors were analyzed, both the crude and adjusted results of our study were found to indicate a greater use of vaccines among men than among women. While most studies previously conducted in Spain on influenza complications (respiratory or cardiovascular disease or diabetes) among high risk groups, report this relationship between gender and influenza vaccination, 17e19,32,34 other studies which have been undertaken elsewhere specifically targeting subjects with chronic respiratory diseases have failed to observe this relationship or even found higher coverages among females. 27e30 Further studies in Spain are thus necessary to explain this association.
Our results also reflect that patients with healthier lifestyles, ex-smokers or nonsmokers, and those who do physical exercise are vaccinated to a greater extent than their less healthy counterparts. Previous studies conducted among persons suffering from lung conditions have identified several unhealthy lifestyles, including tobacco use, alcohol consumption, doing no physical exercise, or having a body mass index of over 30, as negative predictors for influenza vaccination.
17e19, 27, 30 In the multivariate analysis, the influence exerted by the presence of associated asthma and diabetes on influenza coverage was observed. It is only logical to surmise that suffering from a concomitant chronic condition would influence the likelihood of being vaccinated, for at least two reasons: first, suffering from asthma and diabetes constitutes an indication for vaccination per se in Spain, 11 and suffering from another chronic condition has been described by other authors as a positive predictor for the influenza vaccine among chronic lung disease sufferers 18 ; second, suffering from more than one chronic condition would probably result in more frequent use of health-care services, and such subjects are therefore more likely to receive recommendations to be vaccinated from their medical practitioners. Other published studies have likewise observed that patients who make the greatest number of visits to their general practitioner, especially if it is always the same practitioner, have a higher possibility of being vaccinated. 14, 15, 17, 19, 22, 33 This is also coherent with our results, as the reason most cited by patients for being vaccinated was medical indication.
A recent study conducted in five European countries identified a number of key factors that would motivate atrisk populations to seek influenza vaccination, and found that the most important factor was proactive recommendation by a health professional. 31 The vaccination rates for adults (aged 40 years) included in our study and suffering from other chronic conditions for which influenza vaccination is also recommended, such as chronic heart diseases and diabetes, were 64.5% and 62.2% respectively. After adjusting by potential confounders (age and gender) these coverages did not differ significantly for those described among CB sufferers.
Some organizational strategies that have demonstrated their effectiveness for the purpose of enhancing vaccination coverages in target groups and should therefore be recommended include: telephoning or mailing personal reminders; compliance monitoring; using computerized systems to identify high risk patients; improving medical records; drawing up purpose-made influenza vaccination timetables; providing education and giving financial incentives to physicians. 16,32,35e39 The point should also be made that, in Spain, the general practitioner (GP) is the main route for administering influenza vaccination, and that patients are normally vaccinated in primary care health centers. 7, 11, 26 To our knowledge, vaccination recommendation rates in respiratory specialist settings have not been assessed in Spain and should be investigated in the future.
Apart from strategies to improve the implementation of vaccination by providers (general practices and specialists), available and effective interventions, using public communications and educational campaigns, must be used to increase the awareness of and demand for vaccination by persons with chronic lung disease. 16, 31, 32, 35 Educational campaigns must be targeted at patients with the aim of enhancing their knowledge regarding the safety, efficacy and benefits of vaccination. 31,32,35e37 Encouraging vaccination should emphasize the need for such preventive care, regardless of general health status and disease severity, thereby countering possible perceptions that only seriously ill individuals need vaccination.
35e37 Finally, and as mentioned above, lowering the age at which the influenza vaccine recommendation becomes universal is a public health strategy that must be considered. 32 There are a number of possible study limitations. First, the validity of the questions used by the NHS to classify subjects as chronic bronchitis sufferers has not been evaluated. The results of a telephone survey using a specific questionnaire that addressed the frequency of respiratory symptoms and knowledge of COPD among 6758 Spanish subjects aged over 40 years, reported that, among self-reported diagnoses, prevalence of chronic bronchitis or emphysema was 5.8%. This is a figure similar to ours and argues in favor of our sample's representativeness. 40 Nevertheless, both this survey and other authors make the point that underdiagnosis of chronic bronchial diseases is well recognized in epidemiological studies. 40e43 Second, another possible limitation of health surveys is that the use of unvalidated self-report data on vaccination could entail possible bias. In this respect, however, several studies which have compared the results of self-response against medical records observe that self-response on influenza vaccination is highly sensitive and evinces a high degree of agreement. 44, 45 Third, all information obtained within an interview context may be subject to recall errors or to the tendency of individuals to give socially desirable responses. Fourth, information on relevant variables, such as pharmacological treatment, use of other recommended vaccines (pneumococcal vaccine) or duration and severity of chronic bronchitis, is not collected by Spanish National Health Surveys, and may act as a confounding factor in certain associations.
Lastly, the initial NHS response rate was 65%, so the existence of a possible non-response bias should therefore be considered. 21 In conclusion, influenza vaccination coverages among Spanish adults suffering from chronic bronchitis are below desirable levels, thereby making it necessary for strategies to be implemented aimed at improving the use of influenza vaccine among such patients, and particularly among those aged under 65 years, females, subjects with unhealthy lifestyles, and those without other chronic conditions.
